アブストラクト
| Title | がんに関連した血栓症 |
|---|---|
| Subtitle | 臨床講座 |
| Authors | 庄司正昭 |
| Authors (kana) | |
| Organization | 国立がん研究センター中央病院総合内科・循環器内科 |
| Journal | 超音波検査技術 |
| Volume | 48 |
| Number | 1 |
| Page | 58-63 |
| Year/Month | 2023 / 2 |
| Article | 報告 |
| Publisher | 日本超音波検査学会 |
| Abstract | 「■はじめに」がん患者に発症する血栓症はがん関連血栓症(cancer-associated thrombosis:CAT)として, その予後に悪影響を及ぼすことが知られている. しかしCATは複数の病態を包括した疾病であり, その診断法や治療については多岐にわたり, 確立されているとはいえない. CATは深部静脈血栓症(DVT)や肺血栓塞栓症(PE)に代表される静脈血栓塞栓症(VTE), 脳梗塞や心筋梗塞, 腎梗塞, 末梢動脈閉塞などの動脈血栓塞栓症(ATE), さらにTrousseau症候群に関連した播種性血管内凝固異常(DIC)に伴う血栓症や非細菌性血栓性心内膜炎(NBTE)が含まれるとされている. また, カテーテル留置や腫瘍による物理的な血管傷害により, 全身のあらゆる血管で血栓は生じ得る上, 新しい機序の抗がん剤の種類が増加するとともに, 一部では血栓を惹起する副作用が報告されており, CATの病態はますます多様化しているのが実情である. |
| Practice | 医療技術 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110(6): 1723-1729. doi: 10.1182/blood-2006-10-053736. Epub 2007 May 11. PMID: 17496204; PMCID: PMC1976377.
- 2) Li W, Croce K, Steensma DP, et al. Vascular and Meta-bolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J Am Coll Cardiol. 2015; 66(10): 1160-1178. doi: 10.1016/j.jacc.2015.07.025. PMID: 26337996.
- 3) Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017; 70(8): 926-938. doi: 10.1016/j.jacc.2017.06.047. PMID: 28818202; PMCID: PMC5667567.
- 4) Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer. 2013; 49(6): 1404-1413. doi: 10.1016/j.ejca.2012.10.021. Epub 2012 Nov 9. PMID: 23146958.
- 5) Nakamura M, Miyata T, Ozeki Y, et al. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014; 78(3): 708-717. doi: 10.1253/circj.cj-13-0886. Epub 2014 Jan 7. PMID: 24401573.
残りの13件を表示する
- 6) Yamashita Y, Morimoto T, Amano H, et al.; COMMAND VTE Registry Investigators. Anticoagulation Therapy for Venous Thromboembolism in the Real World-From the COMMAND VTE Registry. Circ J. 2018; 82(5): 1262-1270. doi: 10.1253/circj.CJ-17-1128. Epub 2018 Mar 23. PMID: 29576597.
- 7) Ohashi Y, Ikeda M, Kunitoh H, et al. Venous throm-boembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020; 50(11): 1246-1253. doi: 10.1093/jjco/hyaa112. Erratum in: Jpn J Clin Oncol. 2020 Oct 22; 50(11): 1346. PMID: 32715307; PMCID: PMC7579341.
- 8) Khorana AA, Kuderer NM, Culakova E, et al. Develop-ment and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10): 4902-4907. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23. PMID: 18216292; PMCID: PMC2384124.
- 9) Hiraide M, Shiga T, Minowa Y, et al. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients. J Cardiol. 2020; 75(1): 110-114. doi: 10.1016/j.jjcc.2019.06.013. Epub 2019 Aug 12. PMID: 31416782.
- 10) Stevens SM, Woller SC, Kreuziger LB, et al. Antithrom-botic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021; 160(6): e545-e608. doi: 10.1016/j.chest.2021.07.055. Epub 2021 Aug 2. PMID: 34352278.
- 11) Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(10): 1181-1201. doi: 10.6004/jnccn.2021.0047. PMID: 34666313.
- 12) Lee AY, Levine MN, Baker RI, et al.; Randomized Com-parison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer(CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146-153. doi: 10.1056/NEJMoa025313. PMID: 12853587.
- 13) Raskob GE, van Es N, Verhamme P, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378(7): 615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. PMID: 29231094.
- 14) Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial(SELECT-D). J Clin Oncol. 2018; 36(20): 2017-2023. doi: 10.1200/JCO.2018.78.8034. Epub 2018 May 10. PMID: 29746227.
- 15) Agnelli G, Becattini C, Meyer G, et al.; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020; 382(17): 1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. PMID: 32223112.
- 16) Khan F, Rahman A, Carrier M, et al.; MARVELOUS Collaborators. Long term risk of symptomatic recur-rent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: 14363. doi: 10.1136/bmj.l4363. PMID: 31340984; PMCID: PMC6651066.
- 17) Pengo V, Lensing AW, Prins MH, et al.; Thromboem-bolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350(22): 2257-2264. doi: 10.1056/NEJMoa032274. PMID: 15163775.
- 18) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン(2017年改訂版) http://www.j-circ.or.jp/guideline/
